fls.txt
The Company evaluates the profitability of each tax-paying component on a historic cumulative basis and a forward-looking basis while performing this analysis.


item1.txt
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
The accompanying notes are an integral part of these unaudited consolidated financial statements.
All intercompany accounts and transactions have been eliminated in consolidation.
The accompanying Consolidated Balance Sheet as of September 30, 2018 was derived from the audited annual consolidated financial statements as of the period then ended.
In connection with the closing the Company entered into Amendment No.
2 to the Asset Purchase Agreement with the purchaser.
As part of this amendment, liabilities assumed by the purchaser were revised to include accounts payable related to the semiconductor cryogenics business.
Accounts payable and total liabilities of the discontinued operation have also been revised in Note 3, “Discontinued Operations” below.
As of September 30, 2018, the accounts payable balance related to the semiconductor cryogenics business was $11.1 million.
The Company will also revise these balances in previously reported historical periods in the event those periods are presented in future filings.
GENEWIZ was acquired during the three months ended December 31, 2018 and therefore the misclassification did not impact any other historical periods.
Changes in estimates are recorded in the period in which they occur and become known.
Net foreign currency transaction and remeasurement losses totaled $0.5 million and $0.6 million, respectively, during the three months ended June 30, 2019 and 2018 and $1.1 million and $3.1 million, respectively, during the nine months ended June 30, 2019 and 2018.
Foreign exchange contract assets and liabilities are measured and reported at fair value based on observable market inputs and classified within Level 2 of the fair value hierarchy described below due to a lack of an active market for these contracts.
Entities are required to make this election on an instrument-by-instrument basis.
The Company is currently evaluating the impact of this ASU.


item2.txt
Item 2.
In April 2018, we acquired BioSpeciMan Corporation, a Canadian provider of storage services for biological sample materials.
Please refer to Note 5, “Acquisitions” in the Notes to the unaudited consolidated financial statements included in Item 1 "Consolidated Financial Statements" of this Quarterly Report on Form 10-Q for further information on these transactions.
Results of Operations - Revenue for the three months ended June 30, 2019 increased to $203.9 million, or by 18%, as compared to the corresponding period of the prior fiscal year.
Gross margin was 41.0% for the three months ended June 30, 2019 as compared to 38.8% for the corresponding period of the prior fiscal year, an increase of $16.7 million.
Operating expenses were $67.1 million during the three months ended June 30, 2019 as compared to $54.3 million during the corresponding period of the prior fiscal year, an increase of $12.8 million.
Operating income was $16.4 million during the third quarter of fiscal year 2019 as compared to $12.5 million for the corresponding period of the prior fiscal year.
Income from continuing operations was $0.9 million for the third quarter of fiscal year 2019, as compared to $4.8 million for the corresponding period of the prior fiscal year.
Results of Operations - Revenue for the nine months ended June 30, 2019 increased to $581.6 million, or by 23%, as compared to the corresponding period of the prior fiscal year.


item3.txt
Our term loans bear variable interest rates which subject us to interest rate risk.


item4.txt



part2.txt



